Close menu

October 11th, 2023 | 07:50 CEST

New iPhone moment? Apple, NVIDIA, Cantourage

  • Software
  • Innovations
  • Cannabis
  • Technology
Photo credits:

On January 9, 2007, the world changed. That was when Apple introduced its iPhone. Smartphones with touchscreens were previously unknown, but today? Hardly anyone can do without smartphones, tablets and the like! For Apple, the iPhone was the product that changed many things and made the Californians the most valuable company in the world for a time. At the end of 2022, ChatGPT was the next technology to change the world. NVIDIA's stock has been soaring ever since. We highlight NVIDIA and Apple and examine what revolution could change everything for the German company Cantourage.

time to read: 3 minutes | Author: Nico Popp
ISIN: APPLE INC. | US0378331005 , NVIDIA CORP. DL-_001 | US67066G1040 , CANTOURAGE GROUP SE | DE000A3DSV01

Table of contents:

    Philip Schetter, CEO, Cantourage Group SE
    "[...] We are a producer and distributor of medicinal products and thus cover a crucial step in the value chain, especially within the cannabis industry. [...]" Philip Schetter, CEO, Cantourage Group SE

    Full interview


    Apple: iPhone sales are weakening

    Although the market launch of the iPhone was many years ago, smartphones still play a major role for Apple: slightly more than half of sales are still attributable to the iPhone. Another 7.4% relates to the iPad and more than 10% to wearables, which the Company would not sell without its primarily iPhone-based ecosystem. Without question, the introduction of the iPhone has elevated the business to a new level for Apple. But what might be next for the Company?

    Most recently, concerns have been raised about China. After all, Apple makes more than 18% of its sales in China. If the Western world and China increasingly confront each other as rivals and create trade barriers, Apple could also be affected at some point, according to fears. However, the economic situation and inflation have been putting pressure on Apple's figures recently. In the first half of the year, the Company succeeded in increasing sales by 4.4% but lost 9.2% in profit. Sales of the iPhone itself also crumbled by 4.2%. The mixed-reality headset Apple unveiled has yet to ignite with customers so far. It is questionable whether the Apple share will overcome the EUR 180 mark again so quickly. There is currently no pressure to act here.

    NVIDIA: All good, but the valuation...

    The NVIDIA share also experienced its personal "iPhone moment" after introducing the ChatGPT AI a little more than a year ago. Since then, NVIDIA has gained a whopping 258%. The reason: Thanks to its hyper-fast graphics processors, NVIDIA benefits from several megatrends at once, such as AI, but also gaming and cryptocurrencies. After years of growth, however, many sectors are now saturated. Even after the initial AI hype, many companies will likely take their time to orient themselves first and decide on significant investments carefully. **Since NVIDIA is currently valued at a whopping EUR 1.058 billion, corresponding to a price-earnings ratio (P/E) of 263, caution is also urged here.

    Cantourage can scale: German cannabis market picks up speed

    In contrast, the share price performance of German cannabis stock Cantourage was relatively modest - over a six-month period, the stock lost just over 9%. But why is the stock not getting off the ground, even though the German government has set the course for even more far-reaching cannabis liberalization during this time? While cannabis legislation is likely to remain a bit complex in Germany for the foreseeable future, the direction seems clear: More and more patients and recreational users are now getting their hands on the coveted flower in pharmacy quality. Cantourage has established business relationships with manufacturers from all over the world and can also meet this increased demand. In early September, they announced the launch of their own online platform for cannabis prescription in Germany as well. This could pave the way for cannabis to gain broader acceptance in Germany, as it has various medical applications. As a result, the potential customer base for Cantourage continues to grow.

    A digital platform that offers the coveted prescriptions anonymously and quickly will likely meet with a great response from interested consumers. Such platforms already exist today and are seen within the scene as the key to the mass market. The removal of the status as a narcotic should make prescribing and processing via such platforms even more accessible and also cheaper - currently, increased fees are incurred due to the status as a narcotic, among other things. If these and other hurdles fall away from 2024, the cannabis market and with it Cantourage could have its "iPhone moment". The US market research institute BDSA expects that demand for cannabis flowers in Germany could reach 400 t in 2024.

    Growing demand was also anticipated by Cantourage CEO Philip Schetter in an interview from the end of August: "Because cannabis helps many patients with different indications, more patients are likely to try it after the end of its status as a narcotic. This has also been the case in other markets that have now been liberalized, such as Canada." Meanwhile, while Apple's sales with iPhones are weakening and NVIDIA's stock is more expensive than ever, the cannabis boom could also trigger highs on the stock market. The Berlin-based cannabis retailer, with other mainstays in the field of medical consulting, is currently valued at only around EUR 106 million. If the market picks up, the share price could quickly reach double digits again, starting from the current level of around EUR 9.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Armin Schulz on May 23rd, 2024 | 08:30 CEST

    E.ON, MGI - Media and Games Invest, Bayer - Through transformation into a golden future

    • renewableenergies
    • Pharma
    • Innovations
    • Digitization
    • Media

    Sometimes, companies are forced to overhaul their business areas if they wish to survive. A transformation is then unavoidable, and hopefully, the companies emerge stronger in the end. However, there is also the possibility that management will recognize the signs of the times early on and adapt their business models. From traditional companies that are starting a second life through digital innovation to young start-ups that are becoming market leaders through strategic realignments, companies are constantly facing challenges. Their path to a golden future is characterized by visionary decisions, agile adjustments and an unwavering will to improve continuously. We have selected three candidates that are currently undergoing a transformation.


    Commented by Armin Schulz on May 6th, 2024 | 07:15 CEST

    Bayer on the path out of crisis. With their oncology pipelines, are Defence Therapeutics and BioNTech also on the verge of a turnaround?

    • Biotechnology
    • Pharma
    • Cancer
    • Innovations

    After several years of stumbling from one crisis to another, pharmaceutical and agrochemical giant Bayer is now showing signs of a recovery on the horizon. As Bayer navigates its long and rocky road out of the crisis, investors and industry experts are now turning their attention to two other exciting biotech companies: Defence Therapeutics and BioNTech. Both companies, which have caused a sensation in the past mainly due to their revolutionary approaches in cancer therapy, could follow in Bayer's footsteps with their promising oncology pipelines, moving from uncertainty to a bright future.


    Commented by Stefan Feulner on May 6th, 2024 | 07:00 CEST

    Canopy Growth, Globex Mining and Rock Tech Lithium with strong signals

    • Mining
    • Gold
    • Silver
    • Cannabis
    • Lithium

    Now that the precious metals gold and silver are taking a breather after a rally, other markets are becoming the focus of investor interest. In addition to copper, which is likely to reach new highs in the medium term due to supply shortages, lithium, an industrial metal essential for electromobility, continues to work on bottoming out. However, the highlight of the past week in terms of volatility was cannabis stocks, which are expected to remain in focus in the coming weeks.